Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

RSS icon
Thumbnail

What’s in the new version of Graham-Cassidy ACA repeal bill

Multiple risk pools and extra money aimed at states represented by Republican swing votes are among the changes made in a new version of the Graham-Cassidy bill to repeal the Affordable Care Act (ACA) to be released less than five days before a deadline to pass it with a simple majority in the U.S. Senate.

Cancer patients value communication, relationships over technical aspects of care

Cancer patients are more concerned with communication and relationships with physicians over technical aspects of their care, according to a study published in The Joint Commission Journal on Quality and Patient Safety.

Thumbnail

McCain to oppose Graham-Cassidy ACA repeal, possibly sinking bill

The last time Senate Republicans tried to move forward on repealing the Affordable Care Act, it was Sen. John McCain, R-Arizona, who sunk the effort with a dramatic thumbs down. He may have done so again with the latest repeal plan, the Graham-Cassidy bill, announcing Sept. 22 he “cannot in good conscience vote” for the proposal.

Moody’s: Despite ACA uncertainty, health insurers’ outlook stable

U.S. health insurers maintained a stable outlook in the latest report from Moody’s Investor Service, with the rating agency expecting insurance companies “will continue generating solid results owing to disciplined medical management and moderate medical cost trends.”

Hospitals brace for DSH payment cuts

The first set of $43 billion in cuts to Medicaid Disproportionate Share Hospital (DSH) payments will kick in on Oct. 1 and safety-net hospitals have little hope federal action will delay the reductions yet again.

HHS Secretary has spent $300,000 using private planes

Since early May, HHS Secretary Tom Price, MD, has taken at least 24 flights on private charter planes at the agency’s expense, racking up more than $300,000 in costs, according to POLITICO.

Critics of new UC Irvine school worry it seeks to legitimize debunked therapies

The University of California, Irvine recently received a $200 million donation to found a new health sciences college focused on “complementary and alternative medicines and evidence-based self-care.” That definition has some concerned it will aim to incorporate unproven therapies into mainstream medical practices.

Thumbnail

Insurance groups oppose latest ACA repeal plan

Adding to opposition already expressed by physician and hospital groups, America’s Health Insurance Plans (AHIP) and the Blue Cross Blue Shield Association (BCBSA) came out against the Graham-Cassidy legislation to repeal and replace the Affordable Care Act (ACA).

Displaying 4209 - 4216 of 6649

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup